SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3561SYRS Given the persistence of prior price trends, I think that was just the begituck-6/22/2018
3560Given the persistence of prior price trends, I think that was just the beginningsemi_infinite -6/22/2018
3559Syros (SYRS) was off over 17% yesterday on decent volume and no news. I was shotuck-6/22/2018
3558yes, congrats to SRPT holders: as long as Tuck injected SRPT in his firesale thquidditch-6/19/2018
3557Also, given the implications for Translarna, PTCT is down 15+% now. Good thingtuck-6/19/2018
3556Congrat. to all SRPT SH!Miljenko Zuanic-6/19/2018
3555Wave LifeSciences (WVE) off 18% on strong data from a competitor (Sarepta). Chetuck-6/19/2018
3554CBIO closes -64%. I listened to the CC this morning and thought the company hanDewDiligence_on_SI16/18/2018
3553CYTK -16% on P2 announcementmopgcw-6/18/2018
3552Disclaimer: After missing initial rise in NKTR share price, and after decline (Miljenko Zuanic-6/4/2018
3551In light of the ASCO debacle/euphoric cases: my Q is what dictate those,... knowMiljenko Zuanic-6/4/2018
3550CytomX another ASCO loser, now 17%, on sketchy data for CX-072. P1 across many tuck16/4/2018
3549Jounce (JNCE) a two time ASCO loser, as updated data presented yesterday seems etuck-6/4/2018
3548Nektar down 24% premarket on Opdivo + NKTR-214 data Nektar Therapeutics (NASDAQJulius Wong16/4/2018
3547SNDX -22% on tepid data from ENCORE-601 study: investorshub.advfn.comDewDiligence_on_SI-5/17/2018
3546Jounce (JNCE) the main ASCO loser, off 25% after hours on underwhelming responsetuck-5/16/2018
3545EOLS -31% on CRL that shouldn’t have been a surprise to anybody (but evidently wDewDiligence_on_SI15/16/2018
3544Aw, shucks . . . anyhow, as is sometimes the case, the AdCom wasn't tuck-5/10/2018
3543Thanks, as always, for the synopsis.scaram(o)uche-5/8/2018
3542Akcea (AKCA), the IONS spinoff, off 16% after briefing docs come out with a prettuck-5/8/2018
3541Achaogen (AKAO) off 26% on negative AdCom vote for Plazomicin in blood stream intuck-5/3/2018
3540VTVT has a couple of programs in T2D that are nothing special, IMO. DewDiligence_on_SI-4/9/2018
3539Speaking of not seeing effective AD treatments in my lifetime . . . VTVtuck14/9/2018
3538reading that brings back very sad memories.semi_infinite -4/9/2018
3537Here is the link to the ACAD response to CNN, with some facts. Gottlieb also caBiotech Jim14/9/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News